$CMMB

Chemomab Therapeutics Ltd. has announced its Annual General Meeting for April 28, 2026, where shareholders will vote on four key proposals. These proposals include the re-election of two Class II directors, the approval of a refreshed compensation policy, a significant increase in authorized share capital by 8 billion ordinary shares, and the re-appointment of KPMG International's Somekh Chaikin as independent auditors for 2026. The increase in authorized share capital aims to provide the company with flexibility for future financing, strategic transactions, and equity compensation needs.